Experimental validation of UBE2C, BUB1B, RRM2, and TPX2 was successful in 8 paired clinical ccRCC samples, demonstrating that all of them were upregulated in ccRCC (Figure 5(a)). Here, BUB1B is linked to nonpapillary renal cell carcinoma.